相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents
Daniel Gonzalez et al.
CLINICAL MICROBIOLOGY REVIEWS (2013)
Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis
Srinivasa P. S. Rao et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Overton's Rule Helps To Estimate the Penetration of Anti-Infectives into Patients' Cerebrospinal Fluid
Marija Djukic et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Pharmacokinetics and Pharmacodynamics of TMC207 and Its N-Desmethyl Metabolite in a Murine Model of Tuberculosis
Marie-Claude Rouan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions
Maria C. Kjellsson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis
Ian M. Rosenthal et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Structure-Activity Relationships for Amide-, Carbamate-, And Urea-Linked Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Adrian Blaser et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon et al.
LANCET (2012)
High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in Tuberculosis-Infected Rabbit Lungs and Granulomatous Lesions
Brendan Prideaux et al.
ANALYTICAL CHEMISTRY (2011)
PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis
Zahoor Ahmad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Jakko van Ingen et al.
CLINICAL INFECTIOUS DISEASES (2011)
Challenges and opportunities in developing novel drugs for TB
Takushi Kaneko et al.
FUTURE MEDICINAL CHEMISTRY (2011)
Synthesis and Structure-Activity Relationships of Varied Ether Linker Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Andrew M. Thompson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Structure-Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).
Joseph Cherian et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients
Andreas H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies
William A. Denny et al.
FUTURE MEDICINAL CHEMISTRY (2010)
Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices
April Barbour et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Synthesis and Structure-Activity Studies of Biphenyl Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Brian D. Palmer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Dennis A. Smith et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy
Kevin Pethe et al.
NATURE COMMUNICATIONS (2010)
Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects
Ann M. Ginsberg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Structure-Activity Relationships of Antitubercular Nitroimidazoles. 2. Determinants of Aerobic Activity and Quantitative Structure-Activity Relationships
Pilho Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Structure-Activity Relationships of Antitubercular Nitroimidazoles. 1. Structural Features Associated with Aerobic and Anaerobic Activities of 4-and 5-Nitroimidazoles
Pilho Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds
R. Scott Obach et al.
DRUG METABOLISM AND DISPOSITION (2008)
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Ramandeep Singh et al.
SCIENCE (2008)
Rising standards for tuberculosis drug development
Tanjore S. Balganesh et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Tissue concentrations: do we ever learn?
Johan W. Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Interpretation of antibiotic concentration ratios measured in epithelial lining fluid
Sungmin Kiem et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data
Gregory Z. Ferl et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery
Liping Zhou et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?
Ursula Theuretzbacher
CURRENT OPINION IN PHARMACOLOGY (2007)
AAPS-FDA workshop white paper:: Microdialysis principles, application and regulatory perspectives
Chandra S. Chaurasia et al.
PHARMACEUTICAL RESEARCH (2007)
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis:: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy
Radha K. Shandil et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice
Makoto Matsumoto et al.
PLOS MEDICINE (2006)
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis
Eric Nuermberger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis
UH Manjunatha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Tissue distribution and pharmacodynamics: A complicated relationship
JH Lin
CURRENT DRUG METABOLISM (2006)
Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs
M Brunner et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds
AM Marino et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2005)
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis
S Tyagi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models
AJ Lenaerts et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
K Andries et al.
SCIENCE (2005)
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis
EL Nuermberger et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Isoniazid pharmacokinetics-pharmaco dynamics in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents:: Distribution in tissue
M Müller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry
EN Fung et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2003)
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy
HM Ziglam et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females
IJM Duijkers et al.
HUMAN REPRODUCTION (2002)
Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid
JE Conte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Intrapulmonary pharmacokinetics of linezolid
JE Conte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Rational dosing of antibiotics:: the use of plasma concentrations versus tissue concentrations
P Liu et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Animal model pharmacokinetics and pharmacodynamics: a critical review
D Andes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations
JE Conte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes
F Wohnsland et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
CK Stover et al.
NATURE (2000)
Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects
JE Conte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)